Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
isoflurane + propofol
- Development stage
- Phase 3
- Lead developer
- Sedana Medical
- Modality
- Small Molecules
- Administration
- Inhalation, Intravenous
01
Overview
This entry refers to a clinical research context (the MADCO-PC trial, NCT01993836) conducted by **Duke University** that compared two standard anesthetic maintenance strategies: inhalational anesthesia using **isoflurane** and total intravenous anesthesia (TIVA) using **propofol**. The study specifically enrolled elderly patients (aged 60 and older) undergoing major non-cardiac, non-neurological surgeries, including procedures for **lumbar spondylosis**, **cervical spondylosis**, **hip osteoarthritis**, and **knee osteoarthritis**. The primary objective was to determine if the choice of anesthetic agent—isoflurane (a volatile halogenated ether) versus propofol (an alkylphenol)—influences the incidence of postoperative cognitive decline (POCD) and changes in Alzheimer's disease-related biomarkers in the cerebrospinal fluid. Isoflurane acts primarily by modulating GABA-A and glycine receptors and inhibiting NMDA receptors, while propofol acts as a potent positive allosteric modulator of the GABA-A receptor.
- Other names
- isoflurane versus propofolMarkers of Alzheimer's Disease and Cognitive Outcomes After Perioperative Care
02
Targets
GABRR (GABA-A receptor subunit rho)Glycine receptorNMDAR (Glutamate receptor ionotropic, NMDA)GABA-B (Gamma-aminobutyric acid receptor type B)
Beyond the preview
Go deeper on isoflurane + propofol.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on isoflurane + propofol.